home / stock / zyne / zyne news

ZYNE News and Press, Zynerba Pharmaceuticals Inc. From 11/15/22

Stock Information
Company Name: Zynerba Pharmaceuticals Inc.
Stock Symbol: ZYNE
Market: NASDAQ
Website: zynerba.com
Menu
ZYNE ZYNE Quote ZYNE Short ZYNE News ZYNE Articles ZYNE Message Board
Get ZYNE Alerts

News, Short Squeeze, Breakout and More Instantly...
ZYNE - Zynerba rises on orphan drug status for cannabidiol Zygel for 22q11.2 deletion syndrome in EU

The European Commission (EC) granted orphan drug designation to Zynerba Pharmaceuticals' ( NASDAQ: ZYNE ) cannabidiol, the active ingredient in the company's transdermal gel Zygel, to treat 22q11.2 deletion syndrome (22q). The 22q11.2 deletion syndrome is a disord...
ZYNE - Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel(TM) in 22q11.2 Deletion Syndrome

DEVON, Pa., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the European Commission (EC) has granted orphan d...

ZYNE - Zynerba Pharmaceuticals GAAP EPS of -$0.20 beats by $0.03

Zynerba Pharmaceuticals press release ( NASDAQ: ZYNE ): Q3 GAAP EPS of -$0.20 beats by $0.03 . As of September 30, 2022, cash and cash equivalents were $55.9 million, compared to $67.8 million as of December 31, 2021. Management believes that the Company’s c...

ZYNE - Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 $55.9 million in cash and cash equivalents at September 30, 2022; Cash runway into first quarter 2024 ...
ZYNE - Zynerba gets US patent for cannabidiol Zygel to treat 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals ( NASDAQ: ZYNE ) said the U.S. Patent and Trademark Office issued a patent for its transdermal cannabidiol product candidate Zygel to treat 22q11.2 Deletion Syndrome. The patent No. 11,458,109 titled 'Treatment of 22q11.2 Deletion Syndrome ...

ZYNE - Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel(TM) for the Treatment of 22q11.2 Deletion Syndrome

DEVON, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued P...

ZYNE - Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

DEVON, Pa., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, presented a poster at the 2022 National Organization for Rare Disorder...
ZYNE - Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 2022 National Orga...

ZYNE - Zynerba Gets Patent for Fragile X Drug

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,110, titled “Tre...

ZYNE - Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Zynerba Pharmaceuticals ( NASDAQ: ZYNE ) said the U.S. Patent and Trademark Office issued a patent covering methods of treating Fragile X syndrome (FXS) with cannabidiol. The patent no. 11,458,110, titled 'Treatment of Fragile X Syndrome With Cannabidiol' will expire i...
Previous 10 Next 10